Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) Weakness Seen Related to OPZELURA Sample 'Texture Issues' - Mizuho

November 2, 2021 11:02 AM EDT

Mizuho Securities analyst Mara Goldstein weighed in on Incyte (NASDAQ: INCY) following Q3 results and its earnings call. The analyst believes the weakness is likely related to management's comment on a texture issue associated with OPZELURA' (ruxolitinib cream) samples for atopic dermatitis (AD) and is under investigation... More

Incyte (INCY) Tops Q3 EPS by 46c

November 2, 2021 7:16 AM EDT

Incyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.

... More